Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?

被引：1
|
作者：
Park, Jihye [1 ,2 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul, South Korea
来源：
INTESTINAL RESEARCH | 2022年 / 20卷 / 01期
关键词：
NECROSIS FACTOR THERAPY; CROHNS-DISEASE; RISK-FACTORS; SURGERY; VEDOLIZUMAB;
D O I：
10.5217/ir.2021.00170
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [41] Biologic therapy of inflammatory bowel disease
    Baumgart, DC
    Wiedenmann, B
    Dignass, AU
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (10): : 1017 - 1032
  • [42] Biologic therapy for inflammatory bowel disease
    Sands, BE
    INFLAMMATORY BOWEL DISEASES, 1997, 3 (02) : 95 - 113
  • [43] ANALYSIS OF PERIOPERATIVE CLINICAL FEATURES AND COMPLICATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC AGENTS
    Ishii, K.
    Mochida, Y.
    Harigane, K.
    Yamada, Y.
    Mitsugi, N.
    Saito, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 173 - 174
  • [44] EFFICACY AND DURABILITY OF BIOLOGIC THERAPY AFTER FAILURE OF INITIAL AND SUBSEQUENT BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE
    Cusumano, Vivy T.
    Ebriani, Joseph
    Prakash, Preeti
    Dua, Anoushka
    Fansiwala, Kush
    Spartz, Ellen
    Sauk, Jenny S.
    Limketkai, Berkeley N.
    GASTROENTEROLOGY, 2022, 162 (07) : S816 - S816
  • [45] Mesenchymal Stromal Cells Did Not Increase The Risk of Infectious Complications in Patients With Inflammatory Bowel Disease
    Knyazev, Oleg
    Ruchkina, Irina
    Mikhailova, Svetlana
    Konoplyannikov, Anatoliy
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S20
  • [46] Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases
    Fenster, Marc
    Ungaro, Ryan C.
    Hirten, Robert
    Gallinger, Zane
    Cohen, Louis
    Atreja, Ashish
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    Cohen, Benjamin L.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (01) : 257 - 258
  • [47] Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    Melmed, Gil Y.
    Irving, Peter M.
    Casteele, Niels Vande
    Kozuch, Patricia L.
    Raffals, Laura E.
    Baidoo, Leonard
    Bressler, Brian
    Devlin, Shane M.
    Jones, Jennifer
    Kaplan, Gilaad G.
    Sparrow, Miles P.
    Velayos, Fernando S.
    Ullman, Thomas
    Siegel, Corey A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (09) : 1655 - +
  • [48] Pregnancy complications and outcomes in patients with inflammatory bowel disease
    Yokoyama, Y.
    Tanaka, H.
    Nishio, A.
    Sato, T.
    Kawai, M.
    Kamikozuru, K.
    Kita, Y.
    Miyazaki, T.
    Hida, N.
    Hori, K.
    Nakamura, S.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S152 - S153
  • [49] Complications After Colonoscopy in Patients With Inflammatory Bowel Disease
    Wang Peiqi
    Saowanee, Ngamruengphong
    Florin, Selaru
    Alyssa, Parian
    Joanna, Melia
    Mark, Lazarev
    Susan, Hutfless
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S4 - S4
  • [50] Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents
    Papaefthymiou, Apostolis
    Potamianos, Spyros
    Goulas, Antonis
    Doulberis, Michael
    Kountouras, Jannis
    Polyzos, Stergios A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (05): : 852 - 862
12345